- Home
- NCLH vs MIRM Comparison
NCLH vs MIRM Comparison
Compare NCLH & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCLH | MIRM |
|---|---|---|
| Founded | 1966 | 2018 |
| Country | United States | United States |
| Employees | 44500 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 7.2B |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NCLH | MIRM |
|---|---|---|
| Price | $17.28 | $96.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | $24.76 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 15.5M | 698.0K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $5,396,175,000.00 | $19,138,000.00 |
| Revenue This Year | $9.96 | $26.22 |
| Revenue Next Year | $6.60 | $22.04 |
| P/E Ratio | $23.59 | ★ N/A |
| Revenue Growth | ★ 10.71 | N/A |
| 52 Week Low | $14.53 | $63.23 |
| 52 Week High | $27.18 | $130.00 |
Technical Indicators
Market Signals| Indicator | NCLH | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 38.30 | 37.65 |
| Support Level | $14.53 | $95.68 |
| Resistance Level | $21.81 | $98.03 |
| Average True Range (ATR) | 0.61 | 3.75 |
| MACD | -0.26 | -0.15 |
| Stochastic Oscillator | 19.10 | 42.38 |
Price Performance
Historical ComparisonAbout NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 75,000). It operates 35 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet after the pandemic as of May 2022. With 16 passenger vessels on order among its brands through 2037, representing 43,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.